Overview

Azithromycin and Coronary Events Study (ACES)

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

To determine whether treatment with azithromycin decreases the rate of coronary heart disease events among patients with stable documented coronary artery disease.

Phase:

Phase 3

Details

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Azithromycin